JPMorgan Chase & Co. Has $7.80 Million Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

JPMorgan Chase & Co. increased its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 111.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 398,738 shares of the company’s stock after purchasing an additional 210,354 shares during the quarter. JPMorgan Chase & Co.’s holdings in Privia Health Group were worth $7,795,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PRVA. First Horizon Advisors Inc. boosted its position in Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company’s stock valued at $35,000 after buying an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company’s stock worth $47,000 after purchasing an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. acquired a new position in Privia Health Group during the 4th quarter valued at about $51,000. Nisa Investment Advisors LLC boosted its stake in shares of Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company’s stock valued at $98,000 after purchasing an additional 3,249 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Privia Health Group by 48.1% during the 4th quarter. KBC Group NV now owns 5,012 shares of the company’s stock worth $98,000 after buying an additional 1,627 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Wall Street Analyst Weigh In

PRVA has been the subject of several recent research reports. Piper Sandler upped their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Privia Health Group in a research note on Thursday, April 10th. JMP Securities set a $29.00 target price on Privia Health Group in a report on Friday, February 28th. Barclays upped their price target on Privia Health Group from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, April 10th. Finally, Canaccord Genuity Group raised their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Privia Health Group currently has an average rating of “Buy” and a consensus price target of $27.00.

Privia Health Group Stock Performance

NASDAQ:PRVA opened at $23.87 on Thursday. Privia Health Group, Inc. has a 52-week low of $15.92 and a 52-week high of $26.04. The company has a market cap of $2.90 billion, a P/E ratio of 238.72, a P/E/G ratio of 3.47 and a beta of 0.88. The stock’s 50-day simple moving average is $23.83 and its 200 day simple moving average is $21.59.

Insider Activity

In other Privia Health Group news, CFO David Mountcastle sold 5,630 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.20% of the stock is currently owned by insiders.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.